India Biosimilar Market Size, Share, Trends, Industry Analysis, Report 2024-2032
marketoutlook
Biosimilar Market- India
Base Year: 2023
Historical Years: 2018-2023
Forecast Years: 2024-2032
Market Growth Rate: 18.10% (2024-2032)
The India biosimilar market is expanding rapidly, driven by increasing demand for affordable biologic treatments and regulatory support. According to the latest report by IMARC Group, the market is projected to grow at a CAGR of 18.10% from 2024 to 2032.
Download sample copy of the Report: https://www.imarcgroup.com/india-biosimilar-market/requestsample
India Biosimilar Market Trends and Drivers:
-
Rising Demand for Affordable Treatments: The increasing prevalence of chronic illnesses like diabetes, cancer, and rheumatoid arthritis is driving demand for cost-effective alternatives to expensive biologic medicines.
-
Robust Manufacturing Capabilities: India's strong pharmaceutical manufacturing sector, with its experience in producing generic drugs, provides a solid foundation for the development and production of biosimilars.
-
Focus on R&D and Regulatory Approvals: Enhanced investment in research and development, coupled with streamlined regulatory processes, is fostering growth in the biosimilars market.
-
Government Support and Favorable Policies: The Indian government’s support through favorable policies and simplified regulations is stimulating industry development and encouraging investment.
-
Increased Investment from Drug Companies: Significant investments in R&D by Indian pharmaceutical companies aim to develop a diverse range of biosimilar products, targeting both domestic and international markets.
-
Collaborations with Multinational Companies: Partnerships with global pharmaceutical firms are accelerating the commercialization and development of biosimilars, contributing to market growth.
-
Emerging Opportunities for Manufacturers and Patients: New possibilities and innovations in biosimilar treatments are expected to drive continued growth in the Indian biosimilars market.
India Biosimilar Market Industry Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest biosimilars market size in India. It includes forecasts for the period 2024-2032 and historical data from 2018-2023 for the following segments.
Breakup by Molecule:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
- Pegfilgrastim
- Trastuzumab
- Bevacizumab
- Others
Breakup by Indication Insights:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
- Others
Breakup by Manufacturing Type:
- In-house Manufacturing
- Contract Manufacturing
Breakup by Region:
- North India
- West and Central India
- South India
- East and Northeast India
Competitive Landscape:
The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=21512&flag=C
Key highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
